Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies

Electroimmunology and cardiac arrhythmia

(2021) Jana Grune et al.   Nature Reviews Cardiology

A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer

(2021) Masaru Komatsu et al.   BMC GASTROENTEROLOGY

Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies

(2021) Morinobu Seki et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies

(2021) Atsuhiko Sugiyama et al.   INTERNAL MEDICINE

Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review

(2021) Dimitrios C. Ziogas et al.   Frontiers in Oncology

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis

(2020) Yi-Te Huang et al.   Frontiers in Neurology

How to manage patients with corticosteroids in oncology in the era of immunotherapy?

(2020) Mihaela Aldea et al.   EUROPEAN JOURNAL OF CANCER

Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies

(2019) Annette Johansen et al.   NEUROLOGY

Inflammatory myopathy associated with PD-1 inhibitors

(2019) Morinobu Seki et al.   JOURNAL OF AUTOIMMUNITY

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

(2019) Houssein Safa et al.   Journal for ImmunoTherapy of Cancer

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia

(2018) Koutaro Takamatsu et al.   Annals of Clinical and Translational Neurology

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

(2017) D. Makarious et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

(2017) Shigeaki Suzuki et al.   NEUROLOGY

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

(2016) Thomas K. Eigentler et al.   CANCER TREATMENT REVIEWS

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

(2016) Jeffrey S. Weber et al.   ONCOLOGIST

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors

(2015) T. W. Chen et al.   ANNALS OF ONCOLOGY

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis

(2011) Fredrik Romi et al.   JOURNAL OF NEUROLOGY

Anti-Heat Shock Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome

(2010) Geir Helgeland et al.   JOURNAL OF NEUROIMMUNOLOGY

Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis

(2009) Shigeaki Suzuki   ARCHIVES OF NEUROLOGY

The Ice Pack Test in the Differential Diagnosis of Myasthenic Diplopia

(2009) Klio I. Chatzistefanou et al.   OPHTHALMOLOGY

Lifetime course of myasthenia gravis

(2007) David Grob et al.   MUSCLE & NERVE